Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more
Evoke Pharma Inc (EVOK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.155x
Based on the latest financial reports, Evoke Pharma Inc (EVOK) has a cash flow conversion efficiency ratio of -0.155x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-521.96K) by net assets ($3.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evoke Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Evoke Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evoke Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stars Microelectronics (Thailand) PCL
BK:SMT
|
0.044x |
|
Aloys Inc.
KQ:297570
|
-0.007x |
|
Thai Rayon Public Company Limited
BK:TR
|
-0.018x |
|
Microtips Technology
TWO:3285
|
0.003x |
|
Abko Co. Ltd
KQ:129890
|
-0.134x |
|
NFON AG
XETRA:NFN
|
0.048x |
|
01 Quantum Inc.
F:DFK0
|
-0.229x |
|
INNOVANA
NSE:INNOVANA
|
N/A |
Annual Cash Flow Conversion Efficiency for Evoke Pharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Evoke Pharma Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.04 Million | $-5.46 Million | -0.776x | -140.13% |
| 2023-12-31 | $-2.58 Million | $-4.98 Million | 1.933x | +219.67% |
| 2022-12-31 | $4.08 Million | $-6.60 Million | -1.615x | +53.53% |
| 2021-12-31 | $3.56 Million | $-12.35 Million | -3.475x | -268.47% |
| 2020-12-31 | $-3.21 Million | $-6.63 Million | 2.062x | +256.79% |
| 2019-12-31 | $4.38 Million | $-5.76 Million | -1.315x | +24.13% |
| 2018-12-31 | $4.03 Million | $-6.98 Million | -1.734x | +56.93% |
| 2017-12-31 | $2.17 Million | $-8.72 Million | -4.025x | -75.07% |
| 2016-12-31 | $3.79 Million | $-8.71 Million | -2.299x | +24.10% |
| 2015-12-31 | $3.46 Million | $-10.50 Million | -3.029x | -142.01% |
| 2014-12-31 | $9.19 Million | $-11.50 Million | -1.252x | -772.10% |
| 2013-12-31 | $21.18 Million | $-3.04 Million | -0.144x | -261.24% |
| 2012-12-31 | $-19.66 Million | $-1.75 Million | 0.089x | -45.68% |
| 2011-12-31 | $-17.65 Million | $-2.89 Million | 0.164x | -- |